Featured Research

from universities, journals, and other organizations

New Alzheimer's-Associated Mutation May Provide Key To Disease Process

Date:
July 23, 1998
Source:
Massachusetts General Hospital
Summary:
Researchers from the Massachusetts General Hospital (MGH) and colleagues at the Harvard School of Public Health (HSPH) and other institutions have identified a new gene mutation strongly associated with the risk of developing late-onset Alzheimer's disease, the most common form of the brain disorder.

Researchers from the Massachusetts General Hospital (MGH) and colleagues at the Harvard School of Public Health (HSPH) and other institutions have identified a new gene mutation strongly associated with the risk of developing late-onset Alzheimer's disease, the most common form of the brain disorder. Most significantly, the protein coded for by this gene -- known as alpha-2 macroglobulin (A2M) -- interacts with proteins coded by other Alzheimer's-associated genes, suggesting a process that could be key in the disease's development.

"This finding leads us directly to a protein pathway that we think drives the Alzheimer's disease process," says Rudolph Tanzi, PhD, director of the MGH Genetics and Aging Unit and senior author of the report, appearing in the August issue of Nature Genetics. "It could be a powerful new target for the development of drugs to prevent or treat this disease." Tanzi and his colleagues stress that the new mutation is not appropriate for use in diagnosing or predicting Alzheimer's disease. The data also are being presented July 22 in Amsterdam at the Sixth International Conference on Alzheimer's Disease and Related Disorders.

Steven Moldin, PhD, acting chief of the NIMH Genetics Research Branch says, "If replicated, this would prove to be a very major finding in understanding the genetic basis of the common, late-onset form of Alzheimer's disease."

Scientists have long been familiar with the A2M protein and its gene, found on chromo-some 12. A2M is a protease inhibitor, controlling the activity of enzymes that break down other proteins, and has been known to interact with a nerve cell receptor called LRP (low-density lipoprotein receptor-related protein). Two important clues led Tanzi and his colleagues to examine whether mutations in A2M might be associated with Alzheimer's risk. First, two proteins known to be involved with Alzheimer's -- the amyloid precursor protein and apoE -- also interact with LRP. Second, cell culture studies have shown that A2M tightly binds the protein fragment A-beta, the major component of the amyloid plaques found in the brains of Alzheimer's patients. Those studies showed that A2M facilitates the break-down and removal of A-beta from brain cells -- one of the processes that, when it goes wrong, are believed to underlie Alzheimer's.

Following these clues, the MGH-led team looked for associations between mutations in A2M and Alzheimer's using the National Institute of Mental Health (NIMH) Genetics Initiative AD sample, a collection of DNA samples and clinical information from hundreds of families in which more than one individual has Alzheimer's. Employing new family-based association methods -- tools that identify disease genes based on differences observed within families -- they found that a particular gene mutation called A2M-2, in which part of the gene is missing, was strongly associated with Alzheimer's. The family-based association tool used in this study was developed by the HSPH team members.

Deborah Blacker, MD, ScD, of the MGH, the paper's lead author, says, "Alzheimer's is proving to be a very genetically complex disease in which many factors interact to determine who will be affected. In addition to what it may tell us about the disease process, this finding -- if replicated -- will help us sort out the role of additional genetic and environment factors in future studies."

Tanzi explains that the addition of this new piece to the Alzheimer's puzzle suggests a picture of how the disease may develop. "There is little question now that the key event triggering Alzheimer's is the deposition of amyloid plaques, toxic deposits of insoluble A-beta protein fragments, inside the brain. It could be that the A2M, apoE and LRP proteins are involved in a very sensitive, balanced system that breaks down A-beta and harmlessly removes it from brain cells.

"We have a theory that LRP sits in the synapses, the junctions where brain cells communicate with each other, and works with A2M to keep A-beta from accumulating," he continues. "If a defective A2M kept the system from working properly, or if a variant of apoE blocked the usual breakdown process, A-beta plaques could form and clog the synapses -- both slowing nerve signals and preventing the release of growth factors that keep cells healthy. Finding a way to mimic the normal function of A2M with a drug could give us a powerful therapeutic tool."

The level of risk conferred by the A2M-2 mutation appears similar to the risk conferred by the gene variant apoE-4. However, individuals carrying both variants do not seem to have a further increase in their risk. Although apoE appears to affect the age at which symptoms appear, the researchers found that A2M-2 does not affect age of onset. As with apoE-4, the presence or absence of the A2M-2 mutation cannot confirm or rule out whether someone has or will develop Alzheimer's. The researchers also noted that the area of chromosome 12 where the A2M gene is found is not the same area identified as harboring an Alzheimer's disease marker in a 1997 study from Duke University. The MGH team was unable to confirm that finding.

Tanzi and Blacker's coauthors on the Nature Genetics paper are Linda Rodes, Marilyn Albert, PhD, and Bradley Hyman, MD, PhD, of the MGH; Marsha Wilcox, EdD, Nan Laird PhD, and Steven Horvath, PhD, of the Harvard School of Public Health; Rodney Go, PhD, Rodney Perry, PhD, and Bracie Watson, PhD, of the University of Alabama at Birmingham; and Susan Bassett, PhD, and Melvin McInnis, MD, of Johns Hopkins University Medical Institutions. This study was supported by grants from the National Institute of Mental Health, and Tanzi's team also receives support from the National Insitute on Aging, the Alzheimer's Association and the American Health Assistance Foundation.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "New Alzheimer's-Associated Mutation May Provide Key To Disease Process." ScienceDaily. ScienceDaily, 23 July 1998. <www.sciencedaily.com/releases/1998/07/980723070655.htm>.
Massachusetts General Hospital. (1998, July 23). New Alzheimer's-Associated Mutation May Provide Key To Disease Process. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/1998/07/980723070655.htm
Massachusetts General Hospital. "New Alzheimer's-Associated Mutation May Provide Key To Disease Process." ScienceDaily. www.sciencedaily.com/releases/1998/07/980723070655.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins